Dianthus officer plans sale of 20,000 shares

An officer of Dianthus Therapeutics filed a Rule 144 notice to potentially sell 20,000 shares of common stock following an option exercise.

Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. (DNTH) officer Edward Carr filed a notice of proposed sale of securities under Rule 144. The filing covers up to 20,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, arising from an exercise of stock options for cash on September 17, 2026. The shares have an indicated aggregate market value of $2,049,800. Shares of Dianthus common stock were listed on NASDAQ, with 55,934,378 shares outstanding on the referenced date as a baseline figure, not the amount being sold.

Key Figures

Shares to be sold: 20,000 shares Aggregate market value: $2,049,800 Shares outstanding: 55,934,378 shares +1 more

4 metrics

Shares to be sold 20,000 shares Proposed sale of Dianthus common stock under Rule 144 by officer Edward Carr

Aggregate market value $2,049,800 Value associated with the 20,000 DNTH shares covered by the Form 144 notice

Shares outstanding 55,934,378 shares Dianthus common stock outstanding on the referenced date in the Form 144

Proposed transaction date September 17, 2026 Date for exercise of stock options and potential sale under Rule 144

Key Terms

Rule 144, Exercise of Stock Options, aggregate market value, Executive Financial Services

4 terms

Rule 144 regulatory

"see the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 09/17/2026 | Exercise of Stock Options | Issuer"

aggregate market value financial

"Common ... 20000 | 2049800.00 ..."

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Dianthus Therapeutics, Inc. (DNTH)?

It discloses that officer Edward Carr filed a Rule 144 notice for a proposed sale of up to 20,000 shares of Dianthus common stock, to be sold through Morgan Stanley Smith Barney LLC following an exercise of stock options for cash on September 17, 2026.

How many DNTH shares are covered by Edward Carr’s planned Rule 144 sale?

The notice covers up to 20,000 shares of Dianthus Therapeutics common stock. These shares are to be sold in connection with an exercise of stock options for cash, with a referenced date of September 17, 2026 for the transaction and potential sale.

What is the aggregate market value of the DNTH shares in this Form 144?

The Form 144 lists an aggregate market value of $2,049,800 for the 20,000 shares of Dianthus Therapeutics common stock that may be sold under Rule 144 in connection with the option exercise dated September 17, 2026.

Who is the broker for the planned DNTH share sale under Rule 144?

The planned sale of 20,000 DNTH shares is indicated to be through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, in connection with the Rule 144 notice filed by officer Edward Carr.

How many DNTH shares were outstanding in the Form 144 reference?

The filing cites 55,934,378 shares of Dianthus Therapeutics common stock outstanding as of the referenced date. This figure is provided as a baseline for context and is not the number of shares being sold under the Rule 144 notice.

What is the source of the DNTH shares being sold in this Form 144?

The shares to be sold are tied to an exercise of stock options for cash on September 17, 2026. The Form 144 indicates that 20,000 shares of common stock may be sold by officer Edward Carr following that option exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:28 PM Accepted by SEC EDGAR 09/17/2026 - 04:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001273351
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Dianthus Therapeutics, Inc.
SEC File Number	001-38541
Address of Issuer	7 Times Square, 43rd Floor New York NEW YORK 10036
Phone	9299994055
Name of Person for Whose Account the Securities are To Be Sold	EDWARD CARR
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20000	2049800.00	55934378	09/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/17/2026	Exercise of Stock Options	Issuer			20000	09/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Edward Carr
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)